Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells $1,670,298.28 in Stock

Key Points

• Director Thomas Malley sold 50,129 shares of Kiniksa Pharmaceuticals at an average price of $33.32, resulting in a total transaction of approximately $1.67 million, marking a 79.98% decrease in his ownership of the stock.
• Kiniksa Pharmaceuticals reported $0.23 earnings per share for the latest quarter, surpassing the consensus estimate by $0.05, with a total revenue of $156.80 million.
• The stock has recently been rated as a "strong-buy" by Wall Street Zen, with a consensus rating of "Buy" and an average price target of $41.17.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) Director Thomas Malley sold 50,129 shares of the company's stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $33.32, for a total transaction of $1,670,298.28. Following the transaction, the director owned 12,546 shares in the company, valued at $418,032.72. The trade was a 79.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Thomas Malley also recently made the following trade(s):

• On Thursday, August 14th, Thomas Malley sold 78,233 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $33.09, for a total transaction of $2,588,729.97.
• On Tuesday, August 12th, Thomas Malley sold 49,407 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $32.40, for a total value of $1,600,786.80.

Kiniksa Pharmaceuticals International Stock Down 1.7%

NASDAQ KNSA traded down $0.57 during mid-day trading on Tuesday, hitting $33.15. The stock had a trading volume of 371,536 shares, compared to its average volume of 712,135. Kiniksa Pharmaceuticals International, plc has a 52-week low of $17.82 and a 52-week high of $34.55. The company has a market cap of $2.46 billion, a price-to-earnings ratio of 828.96 and a beta of 0.14. The company has a 50 day simple moving average of $29.49 and a 200 day simple moving average of $25.23.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The company had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its position in Kiniksa Pharmaceuticals International by 2.0% in the fourth quarter. Geode Capital Management LLC now owns 492,630 shares of the company's stock valued at $9,744,000 after purchasing an additional 9,654 shares during the period. Wells Fargo & Company MN lifted its position in Kiniksa Pharmaceuticals International by 54.7% during the 4th quarter. Wells Fargo & Company MN now owns 21,102 shares of the company's stock worth $417,000 after acquiring an additional 7,463 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $3,955,000. Barclays PLC lifted its position in shares of Kiniksa Pharmaceuticals International by 11.2% during the fourth quarter. Barclays PLC now owns 71,896 shares of the company's stock worth $1,423,000 after purchasing an additional 7,267 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Kiniksa Pharmaceuticals International by 3.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock valued at $15,262,000 after purchasing an additional 29,300 shares in the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

KNSA has been the subject of a number of research reports. Jefferies Financial Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research report on Tuesday, July 29th. Wedbush reissued an "outperform" rating and set a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Wells Fargo & Company upped their target price on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, July 9th. Finally, Wall Street Zen raised Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 2nd. Six research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $41.17.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.